ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals (ANIP) reported Q2 2026 earnings with total revenue of $266.0 million, up 25.9% YoY, driven by Rare Disease and Generics segments. Adjusted EBITDA rose 32.4% to $71.6 million, exceeding expectations. Cortrophin Gel revenue increased 43.5% to $117.1 million. The company reaffirmed full-year revenue guidance of $1.08B-$1.14B but lowered Cortrophin Gel outlook to $520M-$540M. Management highlighted progress in rare disease focus and sales force expansion.
How this was made
The 30-second read
Why it matters
The most actionable update is the narrowed Cortrophin Gel revenue guidance range, which can change valuation expectations for the rare-disease growth trajectory. Other disclosed items include updated 2026 total revenue, EBITDA, and EPS guidance, plus operational metrics (sales force expansion, prescriber adoption, and new case momentum).
Market read
Traders will likely focus on the Cortrophin Gel guidance reduction and whether the operational momentum metrics (gout prescriber adoption, July new cases) offset the first-half underperformance narrative.
What to watch
Harmony agreement milestone recognition timing ($2M in Q3) and ILUVIEN revenue timing weakness could distort segment comparability, making the headline Cortrophin range change less predictive of full-year demand.
Background
ANI is transitioning toward a rare-disease focus, with Cortrophin Gel as a core growth driver and generics as a secondary segment.
Ticker impact
ANI reported Q2 2026 results and revised 2026 Cortrophin Gel revenue guidance to $520M-$540M from $540M-$575M.
Near-term downside bias versus prior expectations, with volatility likely around rare-disease sales-force execution and Cortrophin demand momentum.
The article discloses a specific full-year revenue range reduction tied to first-half performance, while also providing updated EPS/EBITDA guidance and operational momentum metrics that may cushion the reaction.
Market effects
Rare-disease pharma investors may reprice execution risk for specialty products when guidance is narrowed or lowered.
No clear regional catalyst beyond US-listed biotech sentiment.
Limited, except for potential read-through to specialty ophthalmology and rare-disease commercial execution.
Counterpoint
The Cortrophin Gel guidance cut is framed as first-half timing, while management highlights strong July case initiation and prescriber adoption, which could support a rebound in H2.
Key entities
- companyANI Pharmaceuticals, Inc.
Reported Q2 2026 results and revised 2026 Cortrophin Gel guidance; provided updated rare-disease and generics operational metrics.
- partnerHarmony Biosciences
Referenced as the source of WAKIX royalties and development milestone progress under the Harmony agreement.
